Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Pfizer

Status

Completed

Conditions

Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Treatments

Drug: goserelin

Drug: Radium-223

Drug: leuprorelin

Drug: cabazitaxel

Drug: enzalutamide

Drug: abiraterone

Drug: triptorelin

Drug: apalutamide

Drug: Lutetium-177

Drug: docetaxel

Drug: degarelix

Study type

Observational

Funder types

Industry

Identifiers

NCT05701007

PrCa-RWD (Other Identifier)

C3441057

Details and patient eligibility

About

Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions:

What are the demographic and clinical characteristics of metastatic prostate cancer patients?
How are metastatic prostate cancer patients currently treated and how effective are these treatments?
How does the development of castration-resistance affect patient outcomes?
What is the economic burden of metastatic prostate cancer?

Enrollment

1,083 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022
Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC)
Detection of metastatic prostate cancer

Exclusion criteria

Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014
Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.